Total-Body PET Imaging of Musculoskeletal Disorders

Chaudhari, Abhijit J.; Raynor, William; Gholamrezanezhad, Ali; Werner, Thomas; Rajapakse, Chamith S.; Alavi, Abass

doi:10.1016/j.cpet.2020.09.012

Cited by 17 publications

(9 citation statements)

References 165 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Utilizing [ 15 O]H 2 O PET, changes in muscle blood flow can be accurately quantified, as it has been successfully applied to assess regional blood flow in vital organs such as the brain and heart. Previous studies used [ 15 O]H 2 O PET to evaluate muscle blood flow [37,38].…”

Section: [ 15 O]water ([ 15 O]h 2 O)mentioning

confidence: 99%

Radiopharmaceuticals for Skeletal Muscle PET Imaging

Park,

Lee

et al. 2024

IJMS

View full text Add to dashboard Cite

The skeletal muscles account for approximately 40% of the body weight and are crucial in movement, nutrient absorption, and energy metabolism. Muscle loss and decline in function cause a decrease in the quality of life of patients and the elderly, leading to complications that require early diagnosis. Positron emission tomography/computed tomography (PET/CT) offers non-invasive, high-resolution visualization of tissues. It has emerged as a promising alternative to invasive diagnostic methods and is attracting attention as a tool for assessing muscle function and imaging muscle diseases. Effective imaging of muscle function and pathology relies on appropriate radiopharmaceuticals that target key aspects of muscle metabolism, such as glucose uptake, adenosine triphosphate (ATP) production, and the oxidation of fat and carbohydrates. In this review, we describe how [18F]fluoro-2-deoxy-D-glucose ([18F]FDG), [18F]fluorocholine ([18F]FCH), [11C]acetate, and [15O]water ([15O]H2O) are suitable radiopharmaceuticals for diagnostic imaging of skeletal muscles.

show abstract

Section: [ 15 O]water ([ 15 O]h 2 O)mentioning

confidence: 99%

Radiopharmaceuticals for Skeletal Muscle PET Imaging

Park,

Lee

et al. 2024

IJMS

View full text Add to dashboard Cite

show abstract

“…Figure 4 exemplifies the enhanced organ/bone visualization associated with total-body PET scanning [23]. Musculoskeletal diseases (MSDs): As musculoskeletal diseases can occur anywhere throughout the body, total-body PET/CT is uniquely suitable for the detection and monitoring of these disorders, particularly degenerative or autoimmune arthritis, metabolic bone disease, muscle disorders (sarcopenia), and neoplasms [24]. The long axial coverage, high sensitivity, and excellent spatial resolution of total-body PET/CT will allow clinicians to assess total disease burden and guide clinical decision-making.…”

Section: Non-oncologic Applicationsmentioning

confidence: 99%

Advantages and Applications of Total-Body PET Scanning

Katal¹,

Eibschutz

Saboury

et al. 2022

Diagnostics

Self Cite

View full text Add to dashboard Cite

Recent studies have focused on the development of total-body PET scanning in a variety of fields such as clinical oncology, cardiology, personalized medicine, drug development and toxicology, and inflammatory/infectious disease. Given its ultrahigh detection sensitivity, enhanced temporal resolution, and long scan range (1940 mm), total-body PET scanning can not only image faster than traditional techniques with less administered radioactivity but also perform total-body dynamic acquisition at a longer delayed time point. These unique characteristics create several opportunities to improve image quality and can provide a deeper understanding regarding disease detection, diagnosis, staging/restaging, response to treatment, and prognostication. By reviewing the advantages of total-body PET scanning and discussing the potential clinical applications for this innovative technology, we can address specific issues encountered in routine clinical practice and ultimately improve patient care.

show abstract

“…Furthermore, should any of these markers prove to have high specificity for the disease, it could be possible to create targeted radioligands and use molecular imaging techniques, such as positron emission tomography. 59,60 Recently, systems capable of systemic positron emission tomography imaging at significantly lower dose have become available 61,62 and could provide a unique molecular-level in vivo picture of MTrPs and MPS pathophysiology.…”

Section: Findings and Etiologymentioning

confidence: 99%

Assessment of Myofascial Trigger Points via Imaging

Mazza

Boutin

Chaudhari³

2021

Am J Phys Med Rehabil

Self Cite

View full text Add to dashboard Cite

This study systematically reviewed the published literature on the objective characterization of myofascial pain syndrome and myofascial trigger points using imaging methods. PubMed, Embase, Ovid, and the Cochrane Library databases were used, whereas citation searching was conducted in Scopus. Citations were restricted to those published in English and in peer-reviewed journals between 2000 and 2021. Of 1762 abstracts screened, 69 articles underwent full-text review, and 33 were included. Imaging data assessing myofascial trigger points or myofascial pain syndrome were extracted, and important qualitative and quantitative information on general study methodologies, study populations, sample sizes, and myofascial trigger point/myofascial pain syndrome evaluation were tabulated. Methodological quality of eligible studies was assessed based on the Quality Assessment of Diagnostic Accuracy Studies criteria. Biomechanical properties and blood flow of active and latent myofascial trigger points assessed via imaging were found to be quantifiably distinct from those of healthy tissue. Although these studies show promise, more studies are needed. Future studies should focus on assessing diagnostic test accuracy and testing the reproducibility of results to establish the best performing methods. Increasing methodological consistency would further motivate implementing imaging methods in larger clinical studies. Considering the evidence on efficacy, cost, ease of use and time constraints, ultrasound-based methods are currently the imaging modalities of choice for myofascial pain syndrome/myofascial trigger point assessment.

show abstract

Total-Body PET Imaging of Musculoskeletal Disorders

Cited by 17 publications

References 165 publications

Radiopharmaceuticals for Skeletal Muscle PET Imaging

Radiopharmaceuticals for Skeletal Muscle PET Imaging

Advantages and Applications of Total-Body PET Scanning

Assessment of Myofascial Trigger Points via Imaging

Contact Info

Product

Resources

About